NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









MRM Health

MRM Health

Private
BelgiumHealthcare & Life Scienceshttps://mrmhealth.com/

Last Round

Grant

May 28, 2026

Total Funding Raised

$82.16M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

MRM Health is a clinical-stage biopharmaceutical company that develops innovative microbiome-based live biotherapeutic products for the treatment of chronic inflammatory diseases and immune-oncology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

microbiome therapeuticslive biotherapeutic productsLBPmicrobiome drugbacterial consortiaulcerative colitisgut microbiomeIBDinflammatory bowel diseasemetabolic diseasedrug discoverybiotechgut healthclinical-stage biotechbioinformatics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MRM Health Comps

Public and private peers based on sector, stage, and business model.

MRM Health comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

MRM Health Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 28, 2026
Series BSep 4, 2025
Series AFeb 19, 2020

Key People

Founding team and executive leadership

Sam Possemiers

Chief Executive Officer

Executive Team

Jan Binon

Interim CFO

Executive Team

MRM Health Investors

Notable investors and investment history

MRM Health investors
InvestorRounds
Federal Holding and Investment CompanySeries B
Ackermans & van HaarenSeries B, Series A
Athos KGSeries B
Qbic IISeries A, Series B
BNP Paribas Fortis Private EquitySeries B
BiocodexSeries B
VIBSeries A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 9, 2026

    IND clearance granted for Phase 2b trial of MH002 for ulcerative colitis.

  • Jan 5, 2026

    Presenting at Digestive Disease Week (DDW) 2026 in Chicago.

MRM Health Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

MRM Health Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about MRM Health's valuation, stock price, and market status.

Firmographic Details

HeadquartersBelgium
Employee Range41
Year Founded2020
Last FundingMay 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.